Cargando…
The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
Although erythropoietin-stimulating agents are effective in treating anemia in patients with end-stage kidney disease (ESKD) undergoing hemodialysis, some ESKD patients, especially those with inflammation, continue to suffer from anemia. Statin, an inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) re...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317421/ https://www.ncbi.nlm.nih.gov/pubmed/35887674 http://dx.doi.org/10.3390/jpm12071175 |
_version_ | 1784755052454346752 |
---|---|
author | Tsai, Meng-Hsu Su, Fu-You Chang, Hao-Yun Su, Po-Cheng Chiu, Li-Yun Nowicki, Michal Kao, Chih-Chin Lin, Yen-Chung |
author_facet | Tsai, Meng-Hsu Su, Fu-You Chang, Hao-Yun Su, Po-Cheng Chiu, Li-Yun Nowicki, Michal Kao, Chih-Chin Lin, Yen-Chung |
author_sort | Tsai, Meng-Hsu |
collection | PubMed |
description | Although erythropoietin-stimulating agents are effective in treating anemia in patients with end-stage kidney disease (ESKD) undergoing hemodialysis, some ESKD patients, especially those with inflammation, continue to suffer from anemia. Statin, an inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase with lipid-lowering effects, may have a pleiotropic effect in reducing inflammation, and thus increase hemoglobin (Hb) level. We searched the PubMed, Embase, and Cochrane databases for relevant studies. The population of interest comprised advanced chronic kidney disease (CKD) patients and ESKD patients receiving hemodialysis with statin treatment. The included study designs were randomized control trial/cohort study/pre-post observational study, and outcomes of interest were Hb, erythropoietin resistance index (ERI) and ferritin. PRISMA 2020 guidelines were followed, and risk of bias (RoB) was assessed using the RoB 2.0 tool in randomized controlled trials, and the Newcastle-Ottawa scale (NOS) in cohort studies. We eventually included ten studies (5258 participants), comprising three randomized controlled trials and seven cohort studies. Overall, Hb increased by 0.84 g/dL (95% confidence interval [CI]: −0.02 to 1.70) in all groups using statins, including single-arm cohorts, and by 0.72 g/dL (95% CI: −0.02 to 1.46) in studies with placebo control. Hb levels were higher in the study group than in the control group, with a mean difference of 0.18 g/dL (95% CI: 0.04–0.32) at baseline and 1.0 g/dL (95% CI: 0.13–1.87) at the endpoint. Ferritin increased by 9.97 ng/mL (95% CI: −5.36 to 25.29) in the study group and decreased by 34.01 ng/mL (95% CI: −148.16 to 80.14) in the control group; ferritin fluctuation was higher in the control group. In conclusion, statin may improve renal anemia in ESKD patients receiving hemodialysis and regular erythropoietin-stimulating agents. Future studies with more rigorous methodology and larger sample size study should be performed to confirm this beneficial effect. |
format | Online Article Text |
id | pubmed-9317421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93174212022-07-27 The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis Tsai, Meng-Hsu Su, Fu-You Chang, Hao-Yun Su, Po-Cheng Chiu, Li-Yun Nowicki, Michal Kao, Chih-Chin Lin, Yen-Chung J Pers Med Article Although erythropoietin-stimulating agents are effective in treating anemia in patients with end-stage kidney disease (ESKD) undergoing hemodialysis, some ESKD patients, especially those with inflammation, continue to suffer from anemia. Statin, an inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase with lipid-lowering effects, may have a pleiotropic effect in reducing inflammation, and thus increase hemoglobin (Hb) level. We searched the PubMed, Embase, and Cochrane databases for relevant studies. The population of interest comprised advanced chronic kidney disease (CKD) patients and ESKD patients receiving hemodialysis with statin treatment. The included study designs were randomized control trial/cohort study/pre-post observational study, and outcomes of interest were Hb, erythropoietin resistance index (ERI) and ferritin. PRISMA 2020 guidelines were followed, and risk of bias (RoB) was assessed using the RoB 2.0 tool in randomized controlled trials, and the Newcastle-Ottawa scale (NOS) in cohort studies. We eventually included ten studies (5258 participants), comprising three randomized controlled trials and seven cohort studies. Overall, Hb increased by 0.84 g/dL (95% confidence interval [CI]: −0.02 to 1.70) in all groups using statins, including single-arm cohorts, and by 0.72 g/dL (95% CI: −0.02 to 1.46) in studies with placebo control. Hb levels were higher in the study group than in the control group, with a mean difference of 0.18 g/dL (95% CI: 0.04–0.32) at baseline and 1.0 g/dL (95% CI: 0.13–1.87) at the endpoint. Ferritin increased by 9.97 ng/mL (95% CI: −5.36 to 25.29) in the study group and decreased by 34.01 ng/mL (95% CI: −148.16 to 80.14) in the control group; ferritin fluctuation was higher in the control group. In conclusion, statin may improve renal anemia in ESKD patients receiving hemodialysis and regular erythropoietin-stimulating agents. Future studies with more rigorous methodology and larger sample size study should be performed to confirm this beneficial effect. MDPI 2022-07-19 /pmc/articles/PMC9317421/ /pubmed/35887674 http://dx.doi.org/10.3390/jpm12071175 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tsai, Meng-Hsu Su, Fu-You Chang, Hao-Yun Su, Po-Cheng Chiu, Li-Yun Nowicki, Michal Kao, Chih-Chin Lin, Yen-Chung The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis |
title | The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis |
title_full | The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis |
title_fullStr | The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis |
title_full_unstemmed | The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis |
title_short | The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis |
title_sort | effect of statin on anemia in patients with chronic kidney disease and end-stage kidney disease: a systematic review and meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317421/ https://www.ncbi.nlm.nih.gov/pubmed/35887674 http://dx.doi.org/10.3390/jpm12071175 |
work_keys_str_mv | AT tsaimenghsu theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT sufuyou theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT changhaoyun theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT supocheng theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT chiuliyun theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT nowickimichal theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT kaochihchin theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT linyenchung theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT tsaimenghsu effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT sufuyou effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT changhaoyun effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT supocheng effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT chiuliyun effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT nowickimichal effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT kaochihchin effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis AT linyenchung effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis |